Microbot Medical Expands Manufacturing Capacity Through Strategic Partnership with Sanmina to Support Growing Demand for LIBERTY® Robotic System
Microbot Medical, a medical technology company focused on advancing robotic-assisted endovascular procedures, has announced a strategic manufacturing partnership with Sanmina Corporation, one of the world’s leading integrated manufacturing solutions providers. The collaboration is designed to significantly expand production capacity for the company’s innovative LIBERTY® Endovascular Robotic System, positioning Microbot Medical to meet growing customer demand in both domestic and international markets while strengthening its long-term manufacturing strategy.
The agreement, formalized through a Letter of Agreement (LOA), marks an important milestone for the company as it prepares for broader commercialization of the LIBERTY System. The robotic platform has gained increasing attention from healthcare providers due to its unique design and regulatory achievements. It is currently the only FDA-cleared single-use, remotely operated robotic system developed specifically for peripheral endovascular interventions, offering physicians an innovative approach to performing minimally invasive vascular procedures.
Responding to Rapid Market Growth
The decision to expand manufacturing comes as Microbot Medical experiences growing commercial momentum across the United States. The company has reported increasing adoption of the LIBERTY System by healthcare institutions, with several medical centers expanding their utilization of the technology after initial implementation.
Demand has continued to rise as more hospitals and vascular specialists recognize the potential benefits of robotic-assisted interventions. Existing customers are increasing procedure volumes while new healthcare providers continue moving through various stages of the company’s commercial pipeline.
Beyond the United States, international expansion is also contributing to expected production requirements. Recent regulatory clearance in Israel has opened another important market for the company, while progress toward obtaining the CE Mark is expected to pave the way for commercialization across European countries. Additional regulatory submissions are also underway in other international markets, highlighting the company’s ambitions to establish a broader global presence.
As these commercial opportunities continue to develop, expanding manufacturing capacity has become a strategic priority to ensure that customer demand can be met without delays.
Strategic Manufacturing Partnership
Under the agreement, Sanmina Corporation will manufacture the LIBERTY Endovascular Robotic System, providing Microbot Medical with access to one of the industry’s most experienced global manufacturing organizations.
Sanmina has established itself as a leading provider of integrated manufacturing services across numerous technology sectors, including medical devices. Its expertise spans advanced manufacturing, supply chain management, product lifecycle support, and global production capabilities.
For Microbot Medical, partnering with an experienced manufacturing organization provides several strategic advantages beyond simply increasing production volumes.
The partnership creates an additional manufacturing site that diversifies production operations, reducing dependence on a single manufacturing location. Such diversification can improve operational resilience while helping minimize supply chain risks.
Furthermore, Sanmina’s global manufacturing infrastructure provides flexibility for future expansion as demand continues to increase over the coming years.
Supporting Commercial Expansion
Microbot Medical’s commercial strategy has accelerated considerably over the past year as more physicians gain experience using the LIBERTY System.
Healthcare facilities across several states in the eastern United States have begun integrating the robotic platform into their peripheral vascular programs. As physicians become more familiar with robotic-assisted procedures, utilization rates within existing customer accounts have steadily increased.
At the same time, Microbot Medical continues to add new healthcare institutions through its expanding commercial sales efforts.
The company also plans to broaden its commercial footprint geographically by entering the Western United States later this year. This expansion is expected to substantially increase the number of hospitals and physicians with access to the LIBERTY System.
Increasing production capacity now allows the company to prepare for this broader rollout while maintaining product availability for current customers.
A Unique Robotic Platform
The LIBERTY Endovascular Robotic System occupies a unique position within the field of vascular robotics.
Unlike traditional robotic surgical systems that often require large capital investments and extensive operating room infrastructure, LIBERTY was developed specifically for minimally invasive peripheral endovascular procedures with an emphasis on efficiency and accessibility.
One of its most distinctive characteristics is its single-use robotic architecture, which simplifies workflow while potentially reducing maintenance and sterilization requirements associated with reusable robotic components.
The system also enables physicians to remotely control catheter navigation during procedures, allowing operators to work from a radiation-shielded control station instead of standing directly beside the patient throughout fluoroscopy-guided interventions.
This approach may help reduce physician exposure to ionizing radiation while also decreasing the physical strain associated with wearing heavy protective lead garments during lengthy vascular procedures.
Enhancing Manufacturing Efficiency
Beyond increasing production volume, the Sanmina partnership is expected to improve operational efficiency throughout Microbot Medical’s manufacturing process.
Large-scale manufacturing organizations often possess sophisticated production systems that can optimize workflows, improve quality control, and reduce manufacturing costs through economies of scale.
For an emerging medical technology company preparing for broader commercialization, these efficiencies can play an important role in improving financial performance.
Microbot Medical expects the agreement to contribute to:
- Increased manufacturing capacity
- Improved operational efficiency
- Lower production costs
- Expanded gross margins
- Greater manufacturing flexibility
- Enhanced supply chain resilience
Collectively, these improvements are intended to strengthen the company’s long-term commercial foundation while supporting sustainable growth.
Leadership Expresses Confidence
Sanmina leadership expressed enthusiasm regarding the newly established partnership and its long-term potential.
Asaf Shemesh, CEO of Sanmina Israel, described the agreement as an important milestone for both organizations and emphasized confidence in the collaboration moving forward.
He noted that Sanmina is prepared to support the continued growth of the LIBERTY System while working closely with Microbot Medical to help achieve its strategic objectives. According to Shemesh, the partnership reflects a shared commitment to building a productive long-term relationship capable of supporting increasing commercial demand.
Preparing for Future Growth
Microbot Medical’s operations team also highlighted the importance of expanding manufacturing capacity at this stage of commercialization.
Michal Ahuvia, Director of Operations, explained that increasing adoption across multiple healthcare accounts, combined with growing interest from prospective customers, has created the need for greater production capability.
She noted that hospitals throughout the eastern United States continue increasing utilization of the LIBERTY System, while additional healthcare providers across both existing and newly targeted sales territories are advancing through the company’s commercial pipeline.
According to Ahuvia, partnering with Sanmina will allow the company not only to increase production capacity but also improve manufacturing efficiency while supporting anticipated customer demand over both the near and long term.
She further emphasized that Microbot Medical’s planned expansion into western U.S. markets, together with recent regulatory progress internationally—including clearance in Israel and expectations for CE Mark approval—makes securing a manufacturing partnership with a globally recognized organization particularly important.
International Expansion Accelerates
International regulatory achievements are becoming an increasingly significant component of Microbot Medical’s overall growth strategy.
The company’s recent clearance in Israel represents another important step toward establishing a broader international commercial presence.
Meanwhile, progress toward obtaining CE Mark certification remains a major strategic objective. CE Mark approval would enable commercialization across numerous European countries, significantly expanding the addressable market for the LIBERTY System.
In addition to Europe, Microbot Medical continues pursuing registrations in other international regions where demand for advanced robotic-assisted vascular technologies is expected to grow.
As regulatory approvals accumulate, manufacturing capacity will become increasingly important in supporting simultaneous product launches across multiple markets.
Importance of Manufacturing Scale
Scaling production represents one of the most critical transitions for emerging medical device companies moving from early commercialization toward broader market adoption.
While innovative technology often attracts physician interest, sustained commercial success depends heavily on a company’s ability to manufacture products consistently, maintain high quality standards, manage costs effectively, and deliver products reliably.
Partnering with a global contract manufacturer enables Microbot Medical to leverage established manufacturing expertise rather than building extensive production infrastructure independently.
This strategy allows company leadership to remain focused on innovation, commercialization, regulatory expansion, and customer support while relying on an experienced manufacturing partner for production operations.
Supporting Healthcare Innovation
The partnership also reflects a broader trend within the medical technology industry, where specialized device developers increasingly collaborate with global manufacturing organizations to accelerate commercialization.
As healthcare providers continue adopting advanced robotic platforms, manufacturers capable of delivering high-quality production at scale become essential contributors to innovation.
By combining Microbot Medical’s robotic technology with Sanmina’s manufacturing expertise, both companies aim to support wider availability of robotic-assisted vascular procedures for physicians and patients.
With commercial adoption continuing to increase across the United States, expansion into additional domestic territories planned, and international regulatory progress advancing steadily, Microbot Medical is positioning itself for the next phase of growth.
The agreement with Sanmina provides additional manufacturing capacity while strengthening operational efficiency, improving production flexibility, and supporting future expansion into global markets.
As the LIBERTY Endovascular Robotic System continues gaining acceptance among healthcare providers, the enhanced manufacturing partnership is expected to play a central role in ensuring the company can meet growing customer demand while supporting its broader commercialization strategy.
By proactively investing in scalable production capabilities today, Microbot Medical is laying the foundation for sustained long-term growth in the rapidly evolving field of robotic-assisted endovascular medicine.
Source link: https://ir.microbotmedical.com/
